For Millar, the outcome was obvious

OXFORD - British Biotech Group plc (LSE:BBG, BBIOY) entered the third phase of its post-Keith McCullagh existence when CEO Elliot Goldstein announced that the company was dropping Zacutex, the compound it was developing as a treatment for acute pancreatitis, and would be cutting another 60 employees from its payroll.

The moves last week may have proved bittersweet for Andrew Millar, BBG's ousted head of clinical research who went public a year ago with his charges that Zacutex should be abandoned. Millar, whose revelations about BBG's development of its lead compounds marimastat and Zacutex contributed to the massive letdown of the company's market valuation and led to the departure of founder McCullagh, last week described the company's actions as too long in coming...